INTERNATIONAL NEUROMODULATION SOCIETY

New Post Public Reply Private Reply Replies (1) Message Board
Chanel5
537
INTERNATIONAL NEUROMODULATION SOCIETY


Neuromodulation: An Emerging FieldSCOPE OF NEUROMODULATION ADVANCES

Neuromodulation employs advanced medical device technologies to enhance or suppress activity of the nervous system for the treatment of disease. These technologies include implantable as well as non-implantable devices that deliver electrical, chemical or other agents to reversibly modify brain and nerve cell activity.

Neuromodulation therapies are:Highly targeted to specific areas of the brain or spinal cord, rather than systemic throughout the body such as pharmaceutical treatmentsHighly reversible, allowing physicians to immediately cease treatment with the removal of the stimulating deviceContinuous, improving therapeutic compliance over techniques that rely on fixed intermittent dosing

Caption: Coronal Section of the Human Brain

State of the Field

Normal neural activity is an intricate balance of electrical and chemical signals which can be disrupted by a variety of insults (genetic, chemical or physical trauma) to the nervous system, causing cognitive, motor and sensory impairments. Similar to the way a cardiac pacemaker or defibrillator corrects heartbeat abnormalities, neuromodulation therapies help to reestablish normal neural balance.

Neuromodulation therapies allow focused delivery of modifying agents – e.g. electrical, optical or chemical signals - to targeted areas of the nervous system in order to improve neural function. They range from non-invasive techniques such as transcranial magnetic stimulation (TMS) to techniques involving the surgical implantation of devices to alter activity in discrete areas of the nervous system.

The most common neuromodulation therapy is spinal cord stimulation to treat chronic neuropathic pain. In addition to chronic pain relief, some examples of neuromodulation therapies employed around the world include deep brain stimulation for essential tremor, Parkinson’s disease, dystonia, epilepsy and psychiatric disorders such as depression, obsessive compulsive disorder and Tourette syndrome; sacral nerve stimulation for pelvic disorders and incontinence; gastric and colonic stimulation for gastrointestinal disorders such as dysmotility or obesity; vagal nerve stimulation for epilepsy, obesity or depression; carotid artery stimulation for hypertension, and spinal cord stimulation for ischemic disorders such as angina and peripheral vascular disease.

Benefits of Neuromodulation

Neuromodulation therapies improve peoples’ lives. They provide an alternative to long-term drug therapy for the symptomatic relief of persistent or chronic conditions, which is particularly important when existing drugs are simply ineffective or become problematic for long-term use due to tolerance development, addiction, adverse side-effects or toxicity.

Neuromodulation technologies continuously deliver pharmaceutical agents,  electrical signals or other forms of energy directly to the source of the condition to beneficially alter the way pathologic tissues behave. Because neuromodulation therapies are targeted, they can avoid side effects associated with more systemic or irreversible treatments of nervous system disorders. And being easily reversible , they can provide an important degree of therapeutic control for patients and physicians.

Despite their technological complexity, several studies indicate that for some patients, early use of neuromodulation technologies may be more cost effective at controlling certain conditions overall than medical management approaches, particularly when accounting for the specter of drug dependence. Examples include spinal cord stimulation for the treatment of neuropathic pain and intrathecal baclofen for the treatment severe spasticity.

Caption: Implanted intraspinal Drug Delivery Pump

Neuromodulation on the Horizon

Neuromodulation therapies have been available since the 1960s and have become an integral tool to the healthcare profession. As with most medical technologies, neuromodulation devices have progressed, becoming smaller, more easily implanted and removed, more highly targeted and more cost effective.

Advances in our understanding of and ability to decode the electrical and chemical signaling of the brain, coupled with advances in our ability to engineer probes and technologies of increasing sensitivity and biocompatibility will lead to new treatment indications and increasing clinical utility.

Neuromodulation devices are the fastest growing segment of the overall medical device industry. The number of novel neuromodulation devices approved by the FDA grew 35% in 2007 (from the NeuroInsights Neurotechnology Industry Report.) Promising new neuromodulation therapies address such diverse disorders as migraine, obesity, obsessive compulsive disorder and depression.

Advances in neuromodulation therapies are truly multi-disciplinary, requiring the close collaboration of neuroscientists, engineers and clinicians to reach fruition.

See further information for healthcare providers

(Please note: This information should not be used as a substitute for medical treatment and advice. Always consult a medical professional about any health-related questions or concerns.)

Reviewed Sept. 16, 2010
Content reviewed by medical experts from the International Neuromodulation Society editorial web team

Last Updated on Monday, December 12, 2016 02:14 PM

https://www.neuromodulation.com/treatment

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Veriforce Expands Its Mission with Highwire Acquisition

Updated Category News Views 471

Veriforce Expands Its Mission with Highwire Acquisition The combined expertise delivers stronger safety, compliance, and financial risk management for construction projects worldwide Veriforce, a leader in contractor management and supply chain risk management, has recently announced its acquisition of Highwire. This acquisition is significant in the realm of contractor...

Continue Reading
Tyra Biosciences Achieves Key Preclinical Results, Analysts Upgrades

Updated Category News Views 104

Tyra Biosciences Receives Analyst Upgrade BofA Securities has recently upgraded Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotechnology firm specializing in the creation of next-generation precision medicines. This upgrade highlights investor optimism as the company demonstrates promising results in its drug development process. Focus on Precision Medicine in...

Continue Reading
ConnX Partners with SEPTA for Enhanced Cloud Communication

Updated Category News Views 254

ConnX landed a hefty contract back in 2024 with the Southeastern Pennsylvania Transportation Authority (SEPTA) for a major overhaul of their communications network. The deal’s supposed to create a seamless communication experience, but you know how these things go—desks are skeptical about the actual impact. SEPTA's Communication Crisis: Is Cloud the Answer? SEPTA,...

Continue Reading
Kinepolis Group Announces Upcoming Dividend Payment Details

Updated Category News Views 197

Kinepolis Group Dividend Announcement The Kinepolis Group NV is pleased to inform its shareholders of an upcoming dividend payout, a noteworthy event for investors looking to maximize their returns. Dividend Payment Details The company has officially announced a gross dividend of €0.55 per share. After the deduction of the standard 30% withholding tax, shareholders will...

Continue Reading
Cargotec Board Restructures Ahead of Exciting Name Change

Updated Category News Views 229

Cargotec's Board of Directors Restructuring Meeting Highlights Cargotec Corporation has made significant decisions during its recent Board of Directors meeting, as it prepares for exciting changes ahead. Notably, the Board has elected Jukka Moisio as Chair, continuing a strong leadership footprint. Alongside him, Casimir Lindholm has been appointed Vice Chair, effective...

Continue Reading